Basic Information
Vazkepa
Regulatory Information
EMEA/H/C/005398
March 26, 2021
January 28, 2021
7
August 1, 2024
Company Information
Ireland
88 Harcourt Street Dublin 2 D02DK18
AMARIN PHARMACEUTICALS IRELAND LIMITED
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Indicated to reduce cardiovascular risk as an adjunct to statin therapy.
Overview Summary
Vazkepa is a medicine for reducing the risk of cardiovascular events such as heart attack, stroke and other problems caused by blocked blood circulation. It is for use as add-on treatment in adults being treated with a statin medicine who have high levels of triglycerides (a type of fat) in their blood. Vazkepa is to be used in patients either with a cardiovascular disease (a condition that affects the heart or circulation) or with diabetes and another condition that increases the risk of cardiovascular events. Vazkepa contains the active substance icosapent ethyl.